Vascular Imaging Market Technology Analysis, Procurement Outlook, Competitive Landscape and Forecast, 2026–2035

Vascular Imaging Market Size & Forecast 2035

The global vascular imaging market was valued at USD 7.02 billion in 2025 and is projected to reach USD 13.30 billion by 2035, growing at a CAGR of 6.6% during 2026–2035. The market covers vascular ultrasound, computed tomography angiography, magnetic resonance angiography, catheter-based angiography, intravascular ultrasound, optical coherence tomography, vascular imaging software and directly associated service revenue. General imaging equipment revenue is included only to the extent attributable to vascular applications.

Vascular imaging now spans a clinical pathway rather than a single diagnostic event. Non-invasive ultrasound, CT and MR are used to identify disease and determine severity; angiography guides intervention; and intravascular imaging verifies lesion morphology, stent sizing and procedural outcomes. Growth therefore depends on the volume of cardiovascular, cerebrovascular and peripheral vascular care as well as the speed at which providers connect diagnosis, intervention and follow-up.

The competitive focus is shifting from raw image quality toward diagnostic consistency and procedural efficiency. Artificial intelligence is being used to automate measurements, reduce motion artifacts, segment vessels, quantify stenosis and prioritize urgent examinations. At the same time, hospitals are scrutinizing radiation dose, contrast use, cybersecurity, interoperability, equipment uptime and the availability of trained sonographers and radiologists.

Key Highlights

• Global revenue is forecast to increase by USD 6.28 billion between 2025 and 2035 as vascular disease burden, intervention volumes and replacement of aging systems support demand.
• Vascular ultrasound held an estimated 34.0% share, equal to USD 2.39 billion, in 2025 because it is widely used for carotid, venous, peripheral arterial and abdominal aortic assessment.
• Non-invasive procedures represented 73.0% of market revenue, or USD 5.12 billion, while minimally invasive and intravascular imaging generated 27.0%, or USD 1.90 billion.
• Diagnostic applications accounted for 72.0%, equal to USD 5.05 billion; therapeutic and image-guided applications contributed 28.0%, or USD 1.97 billion.
• Hospitals generated 66.0% of 2025 revenue, reflecting their concentration of CT, MR, angiography and complex interventional workflows.
• North America led with 38.0%, or USD 2.67 billion, while Asia-Pacific represented 26.0%, equal to USD 1.82 billion.
• AI-assisted vessel analysis, angiography-derived physiology and multimodality procedural guidance are becoming important purchasing differentiators.

Market Dynamics: The Shift from Image Acquisition to Vascular Decision Support

Cardiovascular and cerebrovascular workloads sustain equipment demand

Vascular imaging is used across coronary artery disease, stroke, peripheral arterial disease, deep-vein thrombosis, aneurysm, carotid stenosis, renal vascular disease and venous insufficiency. Aging populations and the high prevalence of diabetes, hypertension and obesity are increasing the number of patients who require initial evaluation and repeated monitoring. This creates demand across inexpensive ultrasound examinations and higher-value CT, MR and catheter-based procedures.

Hospitals are also seeing more complex patients with calcified vessels, renal impairment, obesity or prior interventions. These cases place pressure on imaging quality, contrast management and acquisition speed. Systems able to produce diagnostic information in difficult anatomy can reduce repeat examinations and help move patients more quickly toward medical, surgical or endovascular treatment.

Ultrasound remains the front door to vascular assessment

Duplex and Doppler ultrasound remain central because they are non-ionizing, relatively low cost and deployable in outpatient laboratories, hospitals and mobile settings. The principal limitation is operator dependence. Examination quality and reporting consistency vary with experience, particularly in technically difficult patients or small and deep vessels.

Manufacturers are addressing this problem through automated measurements, anatomy recognition, protocol guidance, advanced beamforming and remote collaboration. Portable and handheld ultrasound systems can extend vascular assessment into emergency departments and community settings, but they must still fit quality assurance and credentialing requirements. The market opportunity is strongest where automation shortens scanning time without weakening diagnostic confidence.

CT angiography is gaining from speed and reconstruction advances

CT angiography supports rapid evaluation of the aorta, pulmonary arteries, cerebral circulation, coronary arteries and peripheral runoff. Faster detectors, wider coverage, spectral information and iterative or deep-learning reconstruction are improving visualization while managing radiation and contrast dose. In acute stroke and trauma, reconstruction speed can determine how quickly clinicians identify an occlusion, dissection or active bleed.

CT purchasing is not decided solely by vascular capability because the system serves multiple departments. Vascular revenue therefore depends on protocol breadth, scanner utilization and the ability to process studies efficiently. Automated vessel extraction, calcium subtraction, plaque analysis and structured reporting can increase the clinical value of an installed scanner without requiring a new acquisition.

MR angiography provides a contrast- and radiation-sensitive alternative

MR angiography offers detailed vascular assessment without ionizing radiation and can use non-contrast techniques in selected cases. It is valuable for intracranial, carotid, aortic, renal and peripheral imaging, as well as vessel-wall characterization. Adoption is limited by examination time, motion sensitivity, contraindications, higher capital cost and access constraints.

Compressed sensing, accelerated sequences and AI reconstruction are improving throughput. The commercial opportunity lies in making vascular MR predictable enough for routine scheduling, rather than reserving it for highly specialized cases. Facilities also require protocols adapted to patients with impaired renal function or difficulty remaining still.

Image-guided therapy increases the value of angiography

Catheter angiography remains essential where diagnosis and treatment occur in the same session. Fixed C-arm and mobile systems guide coronary intervention, thrombectomy, embolization, endovascular aneurysm repair and peripheral revascularization. Cone-beam CT, image fusion and vessel navigation are expanding the information available inside the interventional room.

The economic case depends on procedure capacity and room utilization. Systems that reduce setup time, repeat acquisitions or contrast use can improve throughput. However, advanced applications require training and consistent protocol adoption. Capital committees therefore examine whether sophisticated software will be used across enough procedures to justify its cost.

Intravascular imaging moves from selected cases toward procedural optimization

Intravascular ultrasound and optical coherence tomography provide information that angiography alone cannot deliver. They help characterize plaque, measure vessel dimensions, choose stent size, assess expansion and identify edge dissection or malapposition. Wider use is supported by clinical evidence and efforts to improve percutaneous coronary intervention outcomes.

Adoption is restrained by catheter cost, workflow time, reimbursement and the need for interpretation expertise. Automated pullback analysis, co-registration and simplified measurement can reduce these barriers. Vendors that connect intravascular imaging with physiology and angiography on one platform can strengthen their position in interventional cardiology.

AI changes procurement and governance requirements

AI is becoming embedded in image acquisition, reconstruction and interpretation. Examples include automatic Doppler measurements, vessel segmentation, motion correction, plaque quantification and angiography-derived fractional flow reserve. These tools can increase consistency, but hospitals require evidence that they work across patient groups, scanner configurations and clinical settings.

Procurement now includes software licensing, update policy, cybersecurity, data transfer and algorithm monitoring. Buyers also need clarity on whether an AI feature is included with the system, sold as a subscription or charged per examination. This commercial model can create recurring revenue, but it can also slow approval when financial benefits are not measurable.

Workforce and capital constraints limit deployment

Shortages of sonographers, radiologists and interventional staff restrict examination capacity even when disease demand is high. Automation can reduce manual steps but cannot fully replace trained acquisition and clinical interpretation. Training, remote support and standardized protocols have become part of the product value proposition.

High-end CT, MR and angiography systems require substantial capital and facility preparation. Shielding, room construction, power, cooling and service contracts extend the true cost beyond the equipment price. Refurbished systems and long-term managed-service agreements remain important where budgets are constrained, while public tenders frequently emphasize price, local service coverage and guaranteed uptime.

Market Scope

Market Segmentation

By imaging modality

Vascular ultrasound led with 34.0% of 2025 revenue, totaling USD 2.39 billion. The segment includes duplex, Doppler and other ultrasound systems, probes, vascular analysis software and associated service revenue. Its broad use in carotid, venous, arterial and abdominal examinations supports high procedure volume, while replacement demand is moving toward systems with automated measurements and improved imaging in difficult patients.

CT angiography accounted for 25.0%, equal to USD 1.75 billion. Emergency stroke, aortic, pulmonary, coronary and peripheral vascular examinations support utilization. Spectral CT, wide-bore systems and faster reconstruction are raising average system value and expanding clinical reach.

Catheter-based angiography represented 18.0%, or USD 1.26 billion. This category includes fixed and mobile image-guided systems used for diagnostic angiography and endovascular treatment. MR angiography held 14.0%, equal to USD 982.3 million, supported by non-ionizing imaging and advanced soft-tissue characterization.

Intravascular ultrasound and optical coherence tomography generated 7.0%, or USD 491.2 million. Wider use in complex coronary intervention, left-main disease and stent optimization supports growth. Nuclear, lymphatic and other vascular imaging methods accounted for the remaining 2.0%, or USD 140.3 million.

By procedure type

Non-invasive vascular imaging represented 73.0% of 2025 revenue, equal to USD 5.12 billion. Ultrasound, CT angiography and MR angiography dominate this category. Demand is driven by screening, diagnosis, surveillance and treatment planning without arterial catheterization.

Minimally invasive and intravascular imaging accounted for 27.0%, or USD 1.90 billion. Catheter angiography, IVUS and OCT generate fewer procedures but higher revenue per case because they use advanced capital equipment and procedure-specific consumables. This segment is positioned to expand as imaging becomes more tightly linked to therapy selection and procedural verification.

By application

Diagnostic imaging held 72.0% of market revenue, totaling USD 5.05 billion. It includes disease detection, severity assessment, surveillance and pre-procedural planning. The segment benefits from large ultrasound and cross-sectional imaging volumes across hospital and outpatient settings.

Therapeutic and image-guided applications contributed 28.0%, or USD 1.97 billion. Interventional radiology, cardiology, vascular surgery and neurointervention use imaging during revascularization, thrombectomy, aneurysm repair, embolization and stent placement. Its share is expected to rise as fusion imaging, cone-beam CT and intravascular guidance become more common.

By clinical indication

Coronary artery disease generated 28.0% of 2025 revenue, or USD 1.97 billion, supported by coronary CT angiography, catheter angiography, physiology and intravascular imaging. Peripheral arterial and venous disease represented 24.0%, equal to USD 1.68 billion, including lower-extremity arterial studies, venous thrombosis and chronic venous insufficiency.

Cerebrovascular and carotid disease accounted for 20.0%, or USD 1.40 billion, reflecting stroke imaging, carotid ultrasound and neuroangiography. Aortic disease contributed 13.0%, equal to USD 912.2 million. Renal and mesenteric vascular disease held 6.0%, or USD 421.0 million, while oncology-related embolization, lymphatic imaging and other indications represented 9.0%, or USD 631.5 million.

By end user

Hospitals accounted for 66.0% of 2025 revenue, equal to USD 4.63 billion. They operate the largest multimodality fleets and conduct complex emergency and interventional procedures. Academic medical centers also serve as early adopters of photon-counting CT, advanced MR, robotic angiography and intravascular imaging.

Diagnostic imaging centers generated 23.0%, or USD 1.61 billion. Their demand centers on ultrasound, CT and MR systems with high throughput, predictable operating cost and efficient reporting. Ambulatory surgical centers, office-based laboratories and other providers contributed 11.0%, or USD 771.8 million, with purchasing focused on portable ultrasound, compact imaging and systems suited to outpatient vascular procedures.

Regional and Country-Level Analysis

North America

North America held 38.0% of the global market in 2025, equal to USD 2.67 billion. Replacement of advanced imaging fleets, high interventional procedure volumes and broad adoption of imaging software support regional leadership. The United States generated 34.0% of global revenue, or USD 2.39 billion. Hospital consolidation favors enterprise contracts covering equipment, service and informatics, while outpatient migration increases demand for lower-cost systems and predictable financing. Canada represented 3.0%, or USD 210.5 million, and Mexico held 1.0%, or USD 70.2 million.

Europe

Europe accounted for 28.0% of 2025 revenue, totaling USD 1.96 billion. Germany led with 6.0% globally, or USD 421.0 million, supported by a strong hospital base and adoption of advanced CT, MR and angiography. The United Kingdom represented 5.0%, or USD 350.8 million, where replacement demand is balanced against capital backlogs and workforce shortages. France generated 4.0%, or USD 280.7 million, and Italy contributed 3.0%, or USD 210.5 million. The rest of Europe held 10.0%, or USD 701.7 million.

European procurement increasingly evaluates energy use, equipment life, refurbishment and remote service alongside clinical performance. Regulatory clearance timing and country-specific reimbursement influence the adoption of AI and new procedural software. Regional imaging networks also create demand for standardized protocols and vendor-neutral access to images.

Asia-Pacific

Asia-Pacific represented 26.0% of global revenue, equal to USD 1.82 billion, and is expected to gain share through 2035. China accounted for 8.0% globally, or USD 561.3 million, supported by hospital imaging capacity and domestic equipment manufacturing. Japan held 5.0%, or USD 350.8 million, with strong demand for high-resolution ultrasound, CT and MR systems adapted to an aging population.

India represented 4.0%, or USD 280.7 million, where private diagnostic chains and hospital expansion support demand but price and service access remain decisive. South Korea contributed 3.0%, or USD 210.5 million, Australia held 2.0%, or USD 140.3 million, and the rest of Asia-Pacific generated 4.0%, or USD 280.7 million. Local production, compact platforms and tiered product portfolios are important for reaching secondary cities.

Latin America

Latin America accounted for 4.5% of the market, totaling USD 315.8 million. Brazil represented 2.2% globally, or USD 154.4 million, while Argentina, Colombia, Chile and other markets contributed 2.3%, or USD 161.4 million. Demand is concentrated in urban hospitals and private diagnostic networks. Currency risk, import duties and limited specialist service coverage can delay high-value purchases.

Middle East and Africa

The Middle East and Africa held 3.5%, or USD 245.6 million. Gulf Cooperation Council countries accounted for 1.8% globally, or USD 126.3 million, supported by tertiary hospital investment and cardiovascular-care expansion. Israel contributed 0.5%, or USD 35.1 million, and South Africa represented 0.4%, or USD 28.1 million. Other regional markets generated 0.8%, or USD 56.1 million. Managed-service contracts and regional training centers can improve system uptime where technical support is limited.

Competitive Landscape

The market includes diversified imaging companies, ultrasound specialists and interventional-device manufacturers. Siemens Healthineers, GE HealthCare, Philips, Canon Medical Systems, Fujifilm Healthcare, Samsung Medison, Shimadzu, Abbott, Boston Scientific and Terumo are among the important participants.

Large imaging vendors compete through modality breadth, installed-base service and enterprise software. Their advantage is the ability to connect ultrasound, CT, MR and angiography within a common workflow. Interventional specialists compete through IVUS, OCT, physiology and catheter-based systems that generate recurring procedure revenue. The boundary between the groups is narrowing as fusion, co-registration and AI link pre-procedural imaging with treatment guidance.

Competitive differentiation now depends on diagnostic confidence per unit of time. Systems that automate acquisition, recover motion-degraded data, reduce contrast or radiation and simplify interpretation can deliver a stronger operating case than equipment positioned only on technical specifications. Service response and software lifecycle policy remain critical because vascular imaging departments operate under high utilization.

Detailed Company Profiles

Siemens Healthineers AG

Siemens Healthineers covers vascular imaging through ACUSON ultrasound, SOMATOM CT, MAGNETOM MR and ARTIS angiography systems. The ARTIS family supports interventional cardiology, radiology and neurovascular procedures, while syngo applications provide 3D reconstruction, vessel analysis, image fusion and procedural planning. Its cardiovascular software portfolio also includes angiography-derived vessel fractional flow reserve through its Pie Medical Imaging business.

The company’s competitive strategy centers on combining equipment, AI and clinical workflow. Syngo DynaCT applications bring cone-beam CT into the interventional room, and motion-correction tools can recover vascular detail from affected datasets. In March 2026, results from the 2,235-patient FAST III study supported angiography-based vFFR as a safe and effective alternative to pressure-wire FFR for guiding coronary revascularization. This evidence can expand software-based physiology within existing angiography workflows.

GE HealthCare Technologies Inc.

GE HealthCare participates through LOGIQ and Vivid ultrasound, Revolution CT, MR platforms, Allia image-guided systems and advanced visualization software. VesselIQ supports CT angiographic analysis for stenosis, thrombus, stent planning and vessel tortuosity. The company also connects diagnostic and interventional cardiology through ComboLab and EchoPAC solutions.

In August 2026, GE HealthCare introduced Vivid Explorer, Vivid Advanced and Vivid Focus. The systems share the cSound imaging foundation and address high-volume echo laboratories, hospitals and everyday cardiovascular imaging. Vivid Advanced and Vivid Focus support vascular, abdominal and soft-tissue examinations in addition to cardiac work. The portfolio strategy uses common software and AI-assisted workflow across multiple price and care-setting tiers.

Koninklijke Philips N.V.

Philips offers EPIQ and Affiniti ultrasound, Incisive and spectral CT, MR systems, Azurion image-guided therapy and IntraSight interventional applications. Through its intravascular imaging portfolio, the company provides IVUS and physiology technologies used to assess coronary lesions and optimize percutaneous intervention. Azurion integrates live imaging, navigation and procedure-room controls for vascular and structural interventions.

Philips is emphasizing AI-enabled workflow and detector technology. In April 2026, the company received United States clearance for the Rembra CT platform, which is designed for high-throughput acute imaging and cancer-treatment planning. In June 2026, it received clearance for Elevate Plus on EPIQ Elite and Affiniti ultrasound systems, expanding AI-assisted general imaging capabilities. These launches support a strategy of improving access and consistency without requiring every site to purchase the highest-tier platform.

Canon Medical Systems Corporation

Canon Medical provides Aplio ultrasound, Aquilion CT, Vantage MR and Alphenix angiography systems. Aplio products support vascular Doppler, microvascular flow and automated measurement. Aquilion ONE and Aquilion Serve address broad CT angiography and acute imaging needs, while Alphenix systems combine high-definition fluoroscopy, flexible positioning and interventional workflow tools.

Canon’s vascular positioning emphasizes image quality, dose management and productivity across modalities. Its AI-enhanced ultrasound tools are designed to automate repetitive measurements and support reproducibility. The company also uses deep-learning reconstruction in CT and MR to improve image quality or acquisition speed. Its broad portfolio is well suited to hospitals seeking multimodality procurement and consistent service under one vendor relationship.

Recent Developments

• August 28, 2026 – GE HealthCare: GE HealthCare introduced Vivid Explorer, Vivid Advanced and Vivid Focus. The cardiovascular ultrasound systems share cSound architecture and add AI-assisted measurement and workflow functions across high-volume, hospital and routine imaging environments. Vivid Advanced and Vivid Focus also support vascular examinations.
• June 2026 – Philips: Philips received United States clearance for Elevate Plus for the EPIQ Elite and Affiniti ultrasound platforms. The release expanded AI-supported workflow and imaging capabilities relevant to general and vascular ultrasound departments.
• May 2026 – Canon Medical Systems: Canon presented its next generation of AI-enhanced ultrasound productivity tools, focusing on automation, workflow consistency and faster examinations. The development addresses a central vascular-ultrasound constraint: dependence on operator experience and limited sonographer capacity.
• April 22, 2026 – Philips: The United States regulator cleared the Rembra CT platform. Its high-speed reconstruction, wide bore and AI-enabled detector are designed for acute and high-demand imaging, including time-sensitive vascular and stroke workflows.
• March 29, 2026 – Siemens Healthineers and Pie Medical Imaging: FAST III results validated angiography-derived vessel fractional flow reserve as a safe and effective alternative to pressure-wire FFR for revascularization guidance. The randomized study enrolled 2,235 patients across 37 hospitals in seven European countries.

Strategic Takeaways

• Compete on time to clinical decision. Reconstruction speed, automated measurements and structured analysis matter when they reduce the interval between scanning and treatment.
• Connect modalities across the care pathway. Ultrasound, CT, MR, angiography and intravascular imaging should share data and measurements rather than operate as isolated systems.
• Design AI for measurable workflow gains. Hospitals will prioritize algorithms that reduce repeat scans, manual steps, contrast use or interpretation time.
• Address workforce limitations directly. Protocol guidance, remote collaboration and training can expand examination capacity where experienced sonographers and radiologists are scarce.
• Build a lifecycle commercial model. Software upgrades, cybersecurity, preventive maintenance and guaranteed uptime should be priced and presented with the capital equipment.
• Differentiate outpatient configurations. Compact systems, lower infrastructure requirements and predictable service costs are essential as vascular care moves into imaging centers and office-based laboratories.
• Localize service before expanding sales. In growth markets, technician availability, spare parts and applications support can carry more purchasing weight than an advanced feature list.

Trending Topics

Optical Imaging Market

Nuclear Imaging Market

Aerial Imaging Market